Vanda Pharmaceuticals (VNDA) Misses Q3 EPS by 2c
Get Alerts VNDA Hot Sheet
Price: $4.11 +5.66%
Revenue Growth %: +59,101.9%
Financial Fact:
Total operating expenses: 39.14M
Today's EPS Names:
FSI, RELV, NEOM, More
Revenue Growth %: +59,101.9%
Financial Fact:
Total operating expenses: 39.14M
Today's EPS Names:
FSI, RELV, NEOM, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of $0.14, $0.02 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $70.1 million versus the consensus estimate of $75 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 2 reasons why Tesla stock fell on Thursday
- Torrid Holdings Inc. (CURV) Tops Q4 EPS by 4c, provides guidance
- Forian Inc. (FORA) Tops Q4 EPS by 3c, provides outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!